Northstrive and YuvaBio completed Phase II of their AI program, identifying small molecules to enhance mitochondrial health for obesity treatment.
Quiver AI Summary
Northstrive Biosciences and Yuva Biosciences have completed Phase II of their AI Development Program, which utilizes YuvaBio's MitoNova™ platform to identify potential pharmaceutical treatments for obesity, type 2 diabetes, and other cardiometabolic conditions. During this phase, YuvaBio provided Northstrive with a shortlist of small molecule candidates aimed at promoting mitochondrial health and combating obesity and cardiac diseases. The selection was made from 12 curated libraries of compounds, focusing on relevant therapeutic areas. Northstrive is now set to review these compounds for their readiness for experimental testing and clinical development.
Potential Positives
- Northstrive has successfully completed Phase II of the AI Development Program in collaboration with strategic partner Yuva Biosciences, advancing their research on potential pharmaceutical treatments for obesity and cardiometabolic conditions.
- The delivery of a shortlist of small molecule candidates by YuvaBio presents Northstrive with the opportunity to analyze and advance promising compounds towards experimental testing and clinical development, enhancing their drug development pipeline.
- The collaboration utilizes YuvaBio's innovative MitoNova™ AI platform, showcasing Northstrive's commitment to integrating cutting-edge technology in their research and development efforts.
- The focus on promoting mitochondrial health aligns with Northstrive’s therapeutic goals, which may position the company favorably within the expanding market for obesity and metabolic health solutions.
Potential Negatives
- Dependence on Yuva Biosciences for the shortlist of candidates may raise concerns regarding Northstrive's ability to independently develop effective treatments.
- Forward-looking statements indicate uncertainty and potential for disappointing future performance, which may deter investor confidence.
- The acknowledgment of inherent risks associated with future statements highlights Northstrive’s vulnerability to market and regulatory changes.
FAQ
What is the AI Development Program by Northstrive and Yuva Biosciences?
The AI Development Program is a collaboration to develop novel treatments for obesity and type 2 diabetes using AI technology.
What was accomplished in Phase II of the collaboration?
Phase II involved compiling a shortlist of small molecule candidates aimed at promoting mitochondrial health to combat obesity and cardiac diseases.
How does YuvaBio's MitoNova™ platform assist in drug discovery?
MitoNova™ screens chemical compounds to evaluate their predicted impact on targets related to muscle preservation and metabolic health.
What therapeutic focus does Northstrive Biosciences have?
Northstrive focuses on developing aesthetic medicines and addressing obesity, particularly muscle preservation during weight-loss treatments.
Where can I find more information about Northstrive Biosciences?
You can visit their website at www.northstrivebio.com for more information about their projects and initiatives.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
Full Release
- Northstrive Biosciences and Yuva Biosciences previously announced the AI Development Program, a collaboration leveraging MitoNova™, YuvaBio’s proprietary mitochondrial science-focused artificial intelligence platform, to discover and develop novel pharmaceutical treatments for obesity, type 2 diabetes and other cardiometabolic conditions.
- Phase II of this collaboration involved YuvaBio compiling a selection of small molecule candidates with the potential of promoting mitochondrial health to combat obesity and cardiac diseases.
NEWPORT BEACH, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Northstrive Biosciences Inc. (“Northstrive”), a subsidiary of PMGC Holdings Inc. (NASDAQ: ELAB) (the “Company,” “PMGC,” “we,” or “our”), today announced the completion of Phase II of the AI Development Program (“Phase II”) with strategic partner Yuva Biosciences, Inc. (“YuvaBio”). As part of the Phase II objective, YuvaBio delivered to Northstrive a shortlist of small molecule candidates YuvaBio believes has the potential to promote mitochondrial health to combat obesity and cardiac diseases.
YuvaBio completed Phase II by compiling a targeted collection of compounds drawn from 12 curated libraries. These libraries were designed to include molecules with activity across key disease areas—obesity, cardiometabolic disorders, and lipid & glucose metabolism—thereby aligning closely with Northstrive Bio’s therapeutic focus. MitoNova™, YuvaBio’s AI platform, screened the aggregated chemical space to evaluate predicted impact on a specified target involved in muscle preservation and metabolic health. YuvaBio presented Northstrive with a shortlist of compounds ready for biological validation in vitro. Northstrive has the opportunity to review the list of compounds and analyze their potential to be advanced to experimental testing and clinical development.
About Northstrive Biosciences Inc.
Northstrive Biosciences Inc., a PMGC Holdings Inc. company, is a biopharmaceutical company focusing on the development and acquisition of cutting-edge aesthetic medicines. Northstrive Biosciences’ lead asset, EL-22, leverages an engineered probiotic approach to address obesity’s pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. For more information, please visit www.northstrivebio.com .
About PMGC Holdings Inc.
PMGC Holdings Inc. is a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and development across various industries. We are committed to exploring opportunities in multiple sectors to maximize growth and value. For more information, please visit https://www.pmgcholdings.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “believes,” “expects,” “plans,” “potential,” “would” and “future” or similar expressions such as “look forward” are intended to identify forward-looking statements. Forward-looking statements are made as of the date of this press release and are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results. Therefore, you should not rely on any of these forward-looking statements. These and other risks are described more fully in PMGC Holdings’ filings with the United States Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 28, 2025, and its other documents subsequently filed with or furnished to the SEC. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at www.sec.gov . All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
IR Contact:
[email protected]
